Scarica l'app Stockscreener
159.03
2.30%
-3.75
Dopo l'orario di chiusura:
159.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Guardant Health Inc Borsa (GH) Ultime notizie
Bernstein reiterates Guardant Health stock rating on margin outlook - Investing.com
Bernstein reiterates Guardant Health stock rating on margin outlook By Investing.com - Investing.com Canada
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer - biospace.com
GH Maintained by UBS -- Price Target Raised to $225 - GuruFocus
Guardant Health and Collaborators Present 20 Abstracts Showcasing Advances in Liquid Biopsy Tests and Methylation-Based Tumor Classification for Lung Cancer At 2026 World Conference on Lung Cancer - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
GH Initiates Coverage On Guardant Health -- Buy Rating by Rothsc - GuruFocus
Business Insider Names Guardant Health One of America's Most Innovative Businesses - Business Wire
What Makes Guardant Health (GH) a Compelling Bet? - Yahoo Finance
Rothschild Redburn initiates Guardant Health stock with buy rating By Investing.com - Investing.com Canada
Rothschild Redburn initiates Guardant Health stock with buy rating - Investing.com
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - Zacks Investment Research
Guardant Health, Inc. (GH) Stock Analysis: Unveiling a 20% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Guardant Health Stock Price Forecast. Should You Buy GH? - StockInvest.us
GH Looks 144.6% Overvalued on GF Value™ - GuruFocus
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection - Yahoo Finance
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer - Yahoo Finance
AstraZeneca Breast Cancer Drug Etcamah Nets Accelerated FDA Approval With Guardant Health ctDNA Test - GenomeWeb
AmirAli Talasaz Reflects on Lives Lost to Colorectal Cancer – Guardant Health - oncodaily.com
Guardant Health wins FDA nod for Guardant360 CDx as breast cancer companion diagnostic for AstraZeneca camizestrant - Bitget
A Look at Guardant Health Inc (GH) After 3.4% Gain -- GF Value $65.83 vs Price $164.41 - GuruFocus
Guardant Health rises as investors weigh strong growth outlook against patent overhang - Quiver Quantitative
William Blair Maintains Guardant Health(GH.US) With Buy Rating - Moomoo
Guardant Health Shield Test to be Covered by Carelon for Colorectal Cancer Screening - GenomeWeb
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening - Business Wire
Guardant Health, Inc. (GH) Investor Outlook: A 20% Upside Potential Amidst Rapid Revenue Growth - DirectorsTalk Interviews
Guardant Health Inc (GH) Shares Fall 4.2% -- GF Value Says Still Overvalued - GuruFocus
Don't Ignore The Insider Selling In Guardant Health - Sahm
Guardant Suits Against Tempus AI Clear Dismissal Bids - Law360
Guardant Health ordered to pay $245M in patent dispute - Yahoo Finance
Final judgement favours TwinStrand in Guardant patent case - pharmaphorum
Guardant Health Gathering Real World Validation Data for Multi-Cancer Detection Test - GenomeWeb
Guardant Health Inc (GH) Shares Fall 4.4% -- What GF Score of 65 Tells Investors - GuruFocus
Guardant Health, Inc. (GH) Stock Analysis: A Promising Growth Potential with Strong Buy Ratings - DirectorsTalk Interviews
Guardant Health loses patent judgment; ordered to pay $245M - Seeking Alpha
Guardant Health (NASDAQ: GH) insider plans more sales after June disposals - Stock Titan
Ninepoint Partners LP Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Gains as Investors Continue to Weigh Strong Q2 Growth and Shield Momentum - Quiver Quantitative
B of A Securities maintains Buy on Guardant Health, raises target to $190 - scanx.trade
Lisanti Capital Growth LLC Takes $1.59 Million Position in Guardant Health, Inc. $GH - MarketBeat
MSH Capital Advisors LLC Purchases Shares of 6,242 Guardant Health, Inc. $GH - MarketBeat
Eagle Health Investments LP Acquires New Position in Guardant Health, Inc. $GH - MarketBeat
How Investors Are Reacting To Guardant Health (GH) Expanding Blood-Based Cancer Screening Acceptance - simplywall.st
7,149 Shares in Guardant Health, Inc. $GH Purchased by Perigon Wealth Management LLC - MarketBeat
Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock - MarketBeat
How Guardant aims to expand cancer screening with a blood test - MedTech Dive
Guardant Health (NASDAQ: GH) insider plans August sale of 116 shares - Stock Titan
Guardant Health (GH) Surges on FDA Approval and Cancer Screening Momentum - Yahoo Finance
GSA Capital Partners LLP Makes New $1.77 Million Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Stock Analysis: A 23.59% Upside Potential In Precision Oncology - DirectorsTalk Interviews
Informed Momentum Co LLC's Guardant Health Inc(GH) Holding History - GuruFocus
SWS Partners Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health(GH.US) Officer Sells US$7.65 Million in Common Stock - Moomoo
T. Rowe Price discloses 4.9% Guardant Health (GH) holding in 13G/A - Stock Titan
Guardant Health Insider Sold Shares Worth $7,645,218, According to a Recent SEC Filing - marketscreener.com
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate - MarketBeat
Insider Selling: Guardant Health (NASDAQ:GH) Insider Sells $7,645,056.00 in Stock - MarketBeat
Guardant Health CPO Monroe sells $7.6 million in stock By Investing.com - Investing.com South Africa
Guardant Health CPO Monroe sells $7.6 million in stock - Investing.com
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):